ArticleExperimental & molecular medicine2026
CTCF-associated chromatin changes between HOXD1 and HOXD8 contribute to TNBC progression.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Homeobox (HOX) genes and their encoded DNA-binding homeoproteins are important regulators of developmental processes and have been implicated in cancer pathogenesis. Here, we investigated the roles of HOXD1 and HOXD8 across different molecular subtypes of human breast cancer (BC) using a combination of in silico analyses of large-scale patient datasets, in vitro RNA interference (RNAi) phenotyping, and in vivo validation studies. Expression levels of HOXD1 and HOXD8 were differentially altered across BC subtypes and were specifically reduced in the aggressive triple-negative breast cancer (TNBC) subtype. Functional analyses demonstrated that reduced HOXD1 and HOXD8 expression was linked to enhanced invasive, migratory, and proliferative phenotypes. In addition, our molecular analyses suggest that CCCTC-binding factor (CTCF)-associated chromatin changes and DNA methylation status at the HOXD locus contribute to coordinated regulation of HOXD1 and HOXD8 expression in BC cells. Collectively, our findings support a potential tumor-suppressive role for HOXD1 and HOXD8 in TNBC and suggest that the HOXD1/HOXD8 regulatory axis has biological and therapeutic relevance in aggressive BC.
Identifiers
42839017What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.